A chemotherapeutic composition can be configured for subcutaneousadministration forpreferential intralymphatic accumulation while also providing a therapeuticsystemicconcentration that is not toxic. The composition can include apharmaceutically acceptablecarrier, and a nanoconjugate configured for preferential intralymphaticaccumulation aftersubcutaneous administration. The nanoconjugate can include a nanocarrierconfigured forpreferential intralymphatic accumulation after subcutaneous or interstitialadministration, anda plurality of chemotherapeutic agents coupled to the nanocarrier. Thenanoconjugate canhave a dimension of about 10 nm to about 50 nm. Also, the nanoconjugate can beloaded withthe chemotherapeutic agents from about 10% to about 50% w/w. The nanocarriercan be ahyaluronan polymer of about 3 kDa to about 50 kDa. Alternatively, thenanocarrier can be adendrimer.
